(Q37588308)

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

21 January 2018

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Pten is essential for embryonic development and tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Will the real Cowden syndrome please stand up: revised diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN: one gene, many syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Identification of PTEN mutations in metastatic melanoma specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Correlation among pathology, genotype, and patient outcomes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Crosstalk between Pten and Ras signaling pathways in tumor development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Targeting phosphoinositide 3-kinase: moving towards therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Circulating mutant DNA to assess tumor dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP347